Ritambhra Nada

Ritambhra Nada

Auto-generated profile, based on publicly available information

Ritambhra Nada

Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2016 in Nephrology
Verified
Journal Article
Closed access
PDF file
RRRaja Ramachandran
Raja Ramachandran
HHHarsha Kumar Hn
Harsha Kumar Hn
VKVinod Kumar
Vinod Kumar
RNRitambhra Nada
Ritambhra Nada
AYASHOK KUMAR YADAV
ASHOK KUMAR YADAV
HKHarbir Singh Kohli
Harbir Singh Kohli

15 December 2015 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
RRRaja Ramachandran
Raja Ramachandran
VKVinod Kumar
Vinod Kumar
AKAshwani Kumar
Ashwani Kumar
AYASHOK KUMAR YADAV
ASHOK KUMAR YADAV
RNRitambhra Nada
Ritambhra Nada
VJVivekanand Jha
Vivekanand Jha
Antibodies to M-type phospholipase A2 receptor (PLA2R) correlate with clinical activity of primary membranous nephropathy (PMN). Risk alleles in PLA2R1 and HLA-DQA1 genes are associated with PMN. Whether these alleles are associated with the development of anti-PLA2R is unknown. In this prospective study we evaluated anti-PLA2R, enhanced glomerular staining for PLA2R and variations in PLA2R1 and HLA-DQA1 genes in Indian patients with PMN and examined their association with response to treatment. A total of 114 adult PMN patients were studied. Anti-PLA2R was estimated before treatment and after 6 and 12 months of therapy. Enhanced glomerular staining for PLA2R was assessed on fresh frozen tissue. Genotype analysis was done on recruited patients and 95 healthy controls by TaqMan assays for six single-nucleotide polymorphisms (SNPs; rs4664308, rs3749119, rs3749117, rs4664308, rs3828323 and rs2187668). Patients were followed up monthly for a period of 12 months. Of 114 patients, 66.7% showed elevated serum anti-PLA2R by ELISA and 64.9% by indirect immunofluorescence. About 75% had enhanced glomerular staining for PLA2R. A total of 82% of patients had PLA2R-related disease. Reduction in serum anti-PLA2R titer had a significant association with remission of nephrotic syndrome (P = 0.0003) at 6 and 12 months. More than 85% of patients showing >90% reduction in the anti-PLA2R titer achieved remission of the nephrotic state, whereas of those showing <50% reduction in titers, 87.5% had persistent nephrotic state. The SNPs rs3749119, rs3749117, rs4664308 in PLA2R1 and rs2187668 in HLA-DQA1 were significantly associated with PMN. The SNP rs2187668 was associated with anti-PLA2R positivity. Patients with a high-risk genotype had higher anti-PLA2R levels. To conclude, anti-PLA2R and enhanced glomerular PLA2R staining are found in more than two-thirds of Indian PMN cases. A reduction in the anti-PLA2R titer correlated with response to therapy.

1 February 2008 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JKJ. Kurtkoti
J. Kurtkoti
VSV. Sakhuja
V. Sakhuja
KSK. Sud
K. Sud
MMM. Minz
M. Minz
RNR. Nada
R. Nada
VJVivekanand Jha
Vivekanand Jha
Identification of pathological events in the renal allograft using protocol biopsies at predetermined time intervals may yield useful information and improve outcomes. We examined the influence of decisions taken on the basis of 1- and 3-month protocol biopsies findings on 1-year renal allograft function in a prospective randomized study. Out of 102 living-donor allograft recipients, 52 were randomized to undergo protocol biopsies and 50 controls had only indicated biopsies. All acute rejection (AR) episodes (clinical and subclinical) were treated. Calcineurin inhibitor (CNI) dose adjustments were made on clinical judgment. Baseline recipient and donor characteristics, immunosuppressive drug usage, HLA matches and 2-h cyclosporine levels were similar in both groups. At 1 and 3 months, protocol biopsies revealed borderline (BL) changes in 11.5% and 14% patients, AR in 17.3% and 12% and chronic allograft nephropathy (CAN) in 3.8% and 10%. The incidence of clinically evident AR episodes was similar in the two groups, but biopsy group had lower serum creatinine at 6 months (p = 0.0003) and 1 year (p < 0.0001). The renal functions were similar in those with normal histology and BL changes. Protocol biopsies are helpful in detecting subclinical histological changes in the graft and improving short-term renal allograft function.

23 December 2014 in Nephrology
Verified
Journal Article
Closed access
PDF file
CMChetan Mudrabettu
Chetan Mudrabettu
VKVinod Kumar
Vinod Kumar
ARAruna Rakha
Aruna Rakha
AYASHOK KUMAR YADAV
ASHOK KUMAR YADAV
RRRaja Ramachandran
Raja Ramachandran
VJVivekanand Jha
Vivekanand Jha

1 January 2006 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
RSRashim Pal Singh
Rashim Pal Singh
SKSandeep Kumar
Sandeep Kumar
RNRitambra Nada
Ritambra Nada
RPRajendra Prasad
Rajendra Prasad

1 July 2017 in Kidney International Reports
Verified
Journal Article
Open access
RRRaja Ramachandran
Raja Ramachandran
AYASHOK KUMAR YADAV
ASHOK KUMAR YADAV
VKVinod Kumar
Vinod Kumar
VPVenkata Siva Tez Pinnamaneni
Venkata Siva Tez Pinnamaneni
RNRitambhra Nada
Ritambhra Nada
VJVivekanand Jha
Vivekanand Jha
Both cCTX/GCs and CNIs are recommended as first-line agents in the management of PMN. The present study is an extended report of patients randomized to receive TAC/GCs or cCTX/GCs at 2 years post randomization. Seventy patients enrolled in the clinical trial Tacrolimus Combined With Corticosteroids Versus Modified Ponticelli Regimen in Treatment of Idiopathic Membranous Nephropathy: Randomized Control Trial were followed quarterly between 12 and 24 months. At the end of 24 months, 3 patients were lost to follow-up. At 18 months, 66% and 89% (P = 0.04) were in remission in TAC/GCs and cCTX/GCs groups, respectively. At 18 and 24 months, 60% and 86% (P = 0.03) of cases were in remission in the TAC/GCs and cCTX/GCs groups, respectively. At 18 months, 57% and 83% (P = 0.03) of the patients in TAC/GCs and cCTX/GCs groups were in remission without need of any additional immunosuppression (persistent remission) and, at 24 months, 43% and 80% (P = 0.002) were in persistent remission in TAC/GCs and cCTX/GCs groups, respectively. Relapse rate after any remission was 40% and 6.7% in TAC/GCs and cCTX/GCs groups, respectively (P = 0.007). There was an association of aPLA2R titers with remission or resistance (P = 0.006) in relapsing PMN. The significant decrease in eGFR after 12 months of TAC/GCs therapy normalized at 18 and 24 months. At 2 years after randomization, relapse rates are higher for TAC/GCs compared with cCTX/GCs in PMN patients. Thus, cCTX/GCs are better than TAC/GCs in the longer term in PMN patients.